New Study Suggests Possible Link Between Wegovy and Rare 'Eye Stroke' Risk

A recent study has raised concerns about a potential connection between the popular weight-loss drug Wegovy and a rare form of vision loss known as ischemic optic neuropathy (ION), or 'eye stroke.' This condition can cause sudden and painless vision loss due to interrupted blood flow to the optic nerve.

While the findings highlight a possible risk, medical experts stress that the incidence of ION among Wegovy users remains extremely low, and the benefits of the drug for weight management continue to outweigh these rare side effects. Further research is needed to confirm the link and understand the underlying causes.

What Is Ischemic Optic Neuropathy and Why It Matters

Ischemic optic neuropathy (ION) is a sudden loss of vision caused by a blockage in the blood vessels supplying the optic nerve. This condition can affect one or both eyes and leads to rapid vision impairment. Experts describe it as a painless but serious event that requires urgent medical attention.

"This is a very sudden and painless way to lose your eyesight," said Barbara Pierscionek, deputy dean of research and innovation at Anglia Ruskin University. "You can lose vision in one of your eyes or both of them. We're not quite sure exactly how it happens, but it is essentially a blockage of the blood vessels in the eye."—Barbara Pierscionek

Examining the Data: Wegovy vs. Other Semaglutide Drugs

The study analyzed side effect reports submitted to the U.S. FDA from 2017 to 2024, focusing on semaglutide-based drugs including Wegovy, Ozempic, and Rybelsus. Among 31,774 reports, 28 cases of ION were linked to Wegovy and 47 to Ozempic. When adjusted for market time and usage, Wegovy showed a higher proportional risk of ION compared to Ozempic, while Rybelsus showed no notable association.

Both Wegovy and Ozempic contain the same active ingredient, semaglutide, but Wegovy is prescribed at a higher dose for weight management. Whether this higher dose contributes to increased ION risk remains unclear.

Limitations and Need for Further Research

The data reviewed are based on voluntary side effect reports, which are not independently verified and lack detailed medical information. Experts caution that these reports serve as early warning signals rather than definitive proof of causation.

"Such reports are not independently verified and lack important medical details," said Brian Woods, ophthalmology expert at the University of Galway. "More research is needed to determine if Wegovy directly causes ION or if other factors are involved."—Brian Woods

Risk factors for ION include high blood pressure, cardiovascular disease, and diabetes. Since Ozempic is approved for diabetes and Wegovy for weight management, users of both drugs may already have elevated baseline risks.

What This Means for Wegovy Users and the Future

Health authorities like the U.K.'s Medicines and Healthcare products Regulatory Agency advise users of semaglutide drugs to seek immediate medical care if they experience sudden vision changes. However, experts emphasize that the overall risk of eye stroke remains very low and should not deter patients from using Wegovy for weight management.

As Wegovy expands its availability, including higher-dose options, ongoing monitoring and research will be crucial to fully understand and mitigate any potential risks. For now, patients should remain informed and consult healthcare providers about any vision concerns.